Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma.

@article{TsavachidouFenner2010GeneAP,
  title={Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma.},
  author={D Tsavachidou-Fenner and Nizar Tannir and Pheroze Tamboli and Weigang Liu and David Petillo and Bin S. Teh and Gordon B. Mills and Eric Jonasch},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2010},
  volume={21 8},
  pages={
          1599-606
        }
}
BACKGROUND Metastatic renal cell carcinoma (mRCC) patients treated with anti-vascular endothelial growth factor (VEGF) therapies demonstrate promising outcomes but not all patients benefit. Factors that predict response remain to be elucidated. PATIENTS AND METHODS Nephrectomy material from 37 patients with mRCC receiving bevacizumab +/- erlotinib was used for protein and gene expression assessment. Protein lysates were subjected to reverse-phase protein array profiling. RNA extracts were… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 16 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 42 REFERENCES

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer [see comment

  • PH Maxwell, MS Wiesener, GW Chang
  • N Engl J Med
  • 2003
Highly Influential
9 Excerpts

Similar Papers

Loading similar papers…